You are here: Industry Insights > Roche

News List

Roche’s Tecentriq approved for funding in UK in bladder cancer pharmafile
November 02, 2017
In a rare spot of good news for Tecentriq (atezolizumab), after a turbulent period, Roche’s drug has been given the nod by NICE to be funded through the Cancer Drug Fund (CDF).
AZ tops annual R&D spend in UK, Roche is greatest pharma spender worldwide pharmafile
October 25, 2017
New findings of a report by PwC have revealed the biggest spenders in R&D worldwide as global spending hits $700 billion, with Roche coming out on top within the pharmaceutical industry with a total expenditure of $11.4 billion in 2017
Warp Drive and Roche collaborate to develop new classes of antibiotics pharmaceufical-technology
October 18, 2017
US-based firm Warp Drive Bio has formed a strategic alliance with Roche for the discovery and development of several new classes of antibiotics.
Roche links with Warp Drive Bio in antibiotics deal pharmatimes
October 17, 2017
Roche has entered into a collaboration with Warp Drive Bio aiming to discover and develop multiple classes of antibiotics with novel structures and mechanisms of action.
Roche’s skin cancer drug Erivedge pulled from CDF pharmatimes
October 16, 2017
Roche’s Erivedge could be removed from the Cancer Drugs Fund within months after the National Institute for Health and Care Excellence ruled that the drug was not a cost-effective treatment for skin cancer.
Roche's Zika screening test secured approval from FDA biospectrumasia
October 11, 2017
The cobas Zika test is intended to ensure that potentially infected units are not used for blood transfusion.
Roche launches NAVIFY Tumor Board solution to provide decision support to oncology care teams worldpharmanews
October 10, 2017
Roche has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings.
Roche chalks up Swiss approval for multiple sclerosis drug Ocrevus pharmafile
September 29, 2017
Roche has announced that its drug Ocrevus (ocrelizumab) has received marketing approval in Switzerland for the treatment of active relapsing forms of multiple sclerosis (RMS) as well as primary progressive forms of the disease
Roche's Tecentriq scores approvals in metastatic lung and bladder cancer pharmafile
September 28, 2017
The decision in NSCLC was based on data generated from a Phase 2 and Phase 3 trial which demonstrated that Tecentriq enabled patients to live longer than those receiving docetaxel chemotherapy.
Roche receives EU approval of TECENTRIQ biospectrumasia
September 28, 2017
TECENTRIQ provides a new treatment option for people with previously treated locally advanced or metastatic non-small cell cancer (NSCLC).

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page